Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary Intervention on Acute Myocardial Infarction Patients

Inclusion Criteria: * Adults 18-75 years old * AMI diagnosed according to the latest guidelines, including ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI) * The requirement for STEMI was that primary PCI was scheduled within 12 hours of onset. * The requirement for NSTEMI was that coronary angiography was scheduled within 2 hours for very high-risk participants and within 24 hours for high-risk participants . * Regardless of baseline LDL-C levels * Participants voluntarily took part in this study and signed informed consent Exclusion Criteria: * Previous or ongoing treatment for any PCSK9i * Allergy to PCSK9i, statins, or any of the drug ingredients used during the trial * History of hemorrhagic cerebrovascular disease * History of old myocardial infarction/chronic heart failure * History of PCI or coronary artery bypass grafting (CABG) or preparation for CABG * Above Killip level II * Prolonged cardiopulmonary resuscitation (\>20min) * Definite mechanical complications (including perforation of the interventricular septum, or rupture of the papillary tendon bundle or the left ventricular free wall) * malignant arrhythmia * Severe uncontrolled infection, bleeding disorder, end-stage renal disease, severe liver disease, endocrine dysfunction, or the expected less than 1 year survival of malignant tumors * Pregnant or lactating women * Participate in other clinical trials